Emsam

Emsam is a brand name of selegiline, approved by the FDA in the following formulation(s):

EMSAM (selegiline - film, extended release; transdermal)

• 
  Manufacturer: SOMERSET
  
  Approval date: February 27, 2006
  
  Strength(s): 12MG/24HR, 6MG/24HR ^[RLD], 9MG/24HR
  

Has a generic version of Emsam been approved?

No. There is currently no therapeutically equivalent version of Emsam available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Emsam. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Adhesive mixture for transdermal delivery of highly plasticizing drugs
  Patent 7,070,808
  Issued: July 4, 2006
  Inventor(s): Govil; Sharad K. & Weimann; Ludwig J.
  Assignee(s): Mylan Technologies, Inc.
  Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.
  
  Patent expiration dates:
  
  
  • May 10, 2018
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Adhesive mixture for transdermal delivery of highly plasticizing drugs
  Patent 7,150,881
  Issued: December 19, 2006
  Inventor(s): Govil; Sharad K. & Weimann; Ludwig J.
  Assignee(s): Mylan Technologies, Inc.
  Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.
  
  Patent expiration dates:
  
  
  • June 12, 2018
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Adhesive mixture for transdermal delivery of highly plasticizing drugs
  Patent 7,638,140
  Issued: December 29, 2009
  Inventor(s): Govil; Sharad K. & Weimann; Ludwig J.
  Assignee(s): Mylan Technologies, Inc.
  Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.
  
  Patent expiration dates:
  
  
  • May 10, 2018
    
    ✓ 
    Drug product
  
  

See also...

• Emsam Consumer Information (Drugs.com)
• Emsam System Consumer Information (Wolters Kluwer)
• Emsam transdermal Consumer Information (Cerner Multum)
• Emsam Advanced Consumer Information (Micromedex)
• Selegiline Consumer Information (Wolters Kluwer)
• Selegiline Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Selegiline System Consumer Information (Wolters Kluwer)
• Selegiline Consumer Information (Cerner Multum)
• Selegiline transdermal Consumer Information (Cerner Multum)
• Selegiline Advanced Consumer Information (Micromedex)
• Selegiline Transdermal Advanced Consumer Information (Micromedex)
• Selegiline Hydrochloride AHFS DI Monographs (ASHP)